Clinical trial Recruiting at 1 site Observational Ages 21 to 99

Exploring the extremes of coronary artery disease

Official title: Extremes of Coronary Artery Disease and Normality: Understanding Novel Causative and Protective Factors in the Development of Coronary Artery Disease (CAD Extremes)

Run by National Heart Centre Singapore · NCT05775445 · Data updated 2026-11-12

This study is trying to find out why some people with coronary artery disease have serious issues despite not having common risk factors, while others with many risk factors have little to no disease, by looking at their genes and blood samples.

Quick facts

Study typeObservational
Ages21 Years to 99 Years
SexAll
Enrollment1500 (estimated)
SponsorNational Heart Centre Singapore
Academic / other
Locations1 site (Singapore)
StatusRecruiting
StartedMay 30, 2023
Main results expectedDecember 2027
Study endsDecember 2027
Registry record updatedFebruary 21, 2024
Trial IDNCT05775445 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include young adults with significant CAD but no traditional risk factors, as well as older patients with significant CAD and established risk factors.

Probably not a fit

Patients with well-established coronary artery disease and multiple risk factors who do not fit the extreme profiles may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates two distinct groups of patients with coronary artery disease (CAD): those who have significant CAD despite low risk factors and those with multiple risk factors but little to no CAD. The researchers aim to identify molecular markers that may contribute to or protect against acute coronary syndrome (ACS) by analyzing genetic, blood, and atherosclerotic samples from these extreme patient groups. Utilizing single-cell RNA sequencing and a multi-omics approach, the study seeks to uncover insights into the mechanisms underlying these contrasting phenotypes. The findings could enhance understanding of CAD and inform future therapeutic strategies.

Why it matters

Potential benefit: If successful, this study could lead to the identification of new biomarkers for coronary artery disease, improving risk assessment and treatment strategies for patients.

How similar studies have gone: While the study's approach is innovative, previous research has explored similar themes in understanding CAD, though this specific focus on extreme phenotypes is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Group 1:

1. Evidence of significant CAD a. Coronary angiogram or CT coronary angiogram with documented stenosis \>=50% in left main or \>=70% in major epicardial vessel or major branches (LAD, LCX, RCA)

   AND all of the following
2. Age \</= 45 for males and \</= 50 for females
3. Absence of diabetes mellitus
4. Absence of tobacco use
5. No prior CVA or PAD

Group 2

1. Evidence of significant CAD

   1. Coronary angiogram or CT coronary angiogram with documented stenosis \>=50% in left main or \>=70% in major epicardial vessel or major branches (LAD, LCX, RCA)

   AND all of the following
2. Age \</= 45 for males and \</= 50 for females
3. Absence of diabetes mellitus
4. Absence of tobacco use
5. No prior CVA or PAD

Group 3 1. Evidence of significant CAD with one of the following:

1. age\>65
2. Diabetes mellitus
3. End Stage Renal Failure (ESRF)
4. Framingham risk score \>10%

Group 4

1\. No evidence of significant CAD and all of the following

1. Age \<55 for males, \<65 for females
2. Absence of diabetes mellitus
3. Absence of CKD
4. Absence of tobacco use

Exclusion Criteria:

1. Prior history of cancer (excludes pre-cancerous lesions)
2. Expected life expectancy less than 1 year
3. Known autoimmune disease
4. Psychiatric illness
5. Chronic lung disease requiring long term medications or oxygen
6. Chronic infective disease, including tuberculosis, hepatitis B and C; and HIV
7. Inability to comply with study protocol
8. Any other acute or chronic medical or physical condition deemed by the investigator to affect study outcomes

Where it's running

  • National Heart Centre Singapore
    Singapore, Singapore
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.